Rituxan-treatment.com - In-depth Website Analysis
rituxan-treatment.com: Server & Hosting Details
| IPV4 Encoding (Ip2long) | 877165147 |
|---|---|
| Binary IP address | 110100010010000111101001011011 |
| Octal IP address | 6422075133 |
| Hexadecimal IP address | 34487a5b |
Tech Insights on rituxan-treatment.com
Technology
Number of occurences: 3-
CSS -
Html -
Javascript
Javascript
-
Bootstrap.js
-
4721020396.js
-
jquery.min.js
-
utils.min.js
-
granite.min.js
-
main.min.js
-
head.min.js
-
clientlibs.min.js
-
buttons.js
-
riker.js
-
jquery.cors.js
-
foot.min.js
Analytics
Number of occurences 2-
Google Analytics -
Optimizely
Social
Number of occurences: 1- Share This Social Media Buttons
Google Analytics ID
Key Factors Influencing Conversion Rates
-
priority_highNot presentClickable call number
-
priority_highNot presentConversion form (contact form, subscribe)
-
priority_highNot presentClickable email
-
priority_highNot presentCTA (Call To Action) button
-
priority_highNot presentList
-
priority_highNot presentImage
-
done_allPresentViewability on small screens
-
priority_highNot presentFacebook sharing
-
priority_highNot presentTwitter sharing
-
priority_highNot presentLinkedin sharing
HTTPS (SSL) Security Overview for Rituxan-treatment.com
SSL certificate
- name: /OU=GT19065870/OU=See www.geotrust.com/resources/cps (c)15/OU=Domain Control Validated - QuickSSL(R) Premium/CN=www.rituxanforgpampa.com
- subject:
- OU:
- 0: GT19065870
- 1: See www.geotrust.com/resources/cps (c)15
- 2: Domain Control Validated - QuickSSL(R) Premium
- CN: www.rituxanforgpampa.com
- OU:
- hash: 99ac9554
- issuer:
- C: US
- O: GeoTrust Inc.
- OU: Domain Validated SSL
- CN: GeoTrust DV SSL CA - G4
- version: 2
- serialNumber: 152589
- validFrom: 151007191431Z
- validTo: 171009032844Z
- validFrom_time_t: 1444245271
- validTo_time_t: 1507519724
- extensions:
- authorityKeyIdentifier: keyid:0B:50:EC:77:EF:2A:9B:FF:EC:03:A1:0A:FF:AD:C6:E4:2A:18:C7:3E
- authorityInfoAccess: OCSP - URI:http://gu.symcd.com CA Issuers - URI:http://gu.symcb.com/gu.crt
- keyUsage: Digital Signature, Key Encipherment
- extendedKeyUsage: TLS Web Server Authentication, TLS Web Client Authentication
- subjectAltName: DNS:www.rituxanforgpampa.com, DNS:rituxanforgpampa.com
- crlDistributionPoints: Full Name: URI:http://gu.symcb.com/gu.crl
- basicConstraints: CA:FALSE
- certificatePolicies: Policy: 2.23.140.1.2.1 CPS: https://www.geotrust.com/resources/repository/legal
Insights About the rituxan-treatment.com Domain
| Domain name length | 21 |
|---|---|
| Hyphens | Domain contain 1 hyphens! |
| Domain name with Hindi letters: | र इ ट उ ख़ अ ञ - ट र ए अ ट म ए ञ ट . च ओ म |
| Domain name with Hebrew letters: | ר (i) ת (u) כס (a) נ - ת ר (e) (a) ת מ (e) נ ת . ק(c) (ο) מ |
| Domain name with Cyrillic letters: | р и т у ξ a н - т р e a т м e н т . ц о м |
| Domain name with Arabic letters: | ﺭ (i) ﺕ (u) (x) ﺍ ﻥ - ﺕ ﺭ (e) ﺍ ﺕ ﻡ (e) ﻥ ﺕ . (c) (o) ﻡ |
| Domain name with Greek letters: | ρ ι τ υ ξ α ν - τ ρ ε α τ μ ε ν τ . χ ο μ |
| Domain name with Chinese letters: | 艾儿 艾 提 伊吾 艾克斯 诶 艾娜 - 提 艾儿 伊 诶 提 艾马 伊 艾娜 提 . 西 哦 艾马 |
| Domain without Consonants: | rtxn-trtmnt.cm |
| Domain without Vowels: | iuxa-eae.o |
| Alphabet positions: | r18 i9 t20 u21 x24 a1 n14 t20 r18 e5 a1 t20 m13 e5 n14 t20 . c3 o15 m13 |
|
Domain name pattern: V: Vowel, C: Consonant, N: Number |
C V C V C V C C C V V C C V C C . C V C |
Metatags and Values Used on Rituxan-treatment.com
description
Learn about Rituxan® (rituximab), used for Granulomatosis with Polyangiitis (formerly Wegener's Granulomatosis) and Microscopic Polyangiitis treatment. Rituxan® (Rituximab) is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent, Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy, Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy, Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens, Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rituxan is not recommended for use in patients with severe, active infections. BOXED WARNINGS: Rituxan administration can result in serious, including fatal, adverse reactions. These include infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy. BOXED WARNINGS: WARNING: FATAL INFUSION REACTIONS, SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY. Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion reactions. Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan. Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation. Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan [see Warnings and Precautions. WARNINGS AND PRECAUTIONS: Tumor Lysis Syndrome: Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within 12-24 hours after the first infusion of Rituxan in patients with NHL. Infections: Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Rituxan-based therapy. Cardiovascular: Discontinue infusions for serious or life‑threatening cardiac arrhythmias. Renal: Severe, including fatal, renal toxicity can occur after Rituxan administration in patients with NHL. Bowel Obstruction and Perforation: Abdominal pain, bowel obstruction and perforation, in some cases leading to death, can occur in patients receiving Rituxan in combination with chemotherapy. ADDITIONAL IMPORTANT SAFETY INFORMATION: The most common Grade 3 or 4 adverse reactions in clinical trials of NHL and CLL were infusion reactions, neutropenia, leukopenia, anemia, thrombocytopenia, and infections. Additionally, lymphopenia and lung disorder were seen in NHL trials; and febrile neutropenia, pancytopenia, hypotension, and hepatitis B were seen in CLL trials. The most common adverse reactions (incidence ≥25%) in clinical trials of NHL and CLL were infusion reactions. Additionally, fever, lymphopenia, chills, infection, and asthenia were seen in NHL trials; and neutropenia was seen in CLL trials. For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide. Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
keywords
rituxan, rituximab, genentech, roche, wegener's Granulomatosis, gpa therapy, mpa therapy, Granulomatosis with Polyangiitis treatment, Microscopic Polyangiitis treatment, vasculitis medication, auto immune disease, low white blood cell count, inflammation in the blood, anca-associated vasculitis medication, AAV
viewport
width=device-width, initial-scale=1
Main nameservers for rituxan-treatment.com
- dnadns2e.gene.com
- dnadns4e.gene.com
- dnadns3e.gene.com
Target
- postmaster.no.email.please
Common Mistyped Domains
Common spelling mistakes people make when searching for rituxan-treatment.com.
Possible TLDs
List of possible domain names with other tlds